



In a clinical study
Higher patient ratings of pain relief seen with Aleve® than with acetaminophen

In a trial in dental pain, 3 times more patients reported the overall effectiveness of Aleve® as very good or excellent versus acetaminophen. A greater percentage of patients rated acetaminophen as good or fair versus Aleve®.⁵



In a clinical study
Proven duration of Aleve® vs ibuprofen

A single-center, randomized, double-blind, placebo-controlled study demonstrated that the duration of pain relief after a single dose of Aleve® 440 mg was significantly longer than ibuprofen 400 mg in post-surgical dental pain. Significantly fewer Aleve®-treated subjects required rescue medication over a 24-hour period.⁷



Professional guidelines recommend NSAIDs as first-line minor pain treatment

In response to the increase in prescription opioid abuse, dental associations now recommend NSAIDs like Aleve® over opioids.^{2,3} The American Dental Association recommends NSAIDs like naproxen as first-line therapy for acute pain management,² and the American Association of Oral and Maxillofacial Surgeons recommends NSAIDs like naproxen as a first-line analgesic therapy for the management of acute and postoperative pain.³ Aleve® is indicated for the temporary relief of minor aches and pains.

Summary

Aleve® is an OTC pain reliever with proven efficacy, duration, and a similar median time to onset of action as acetaminophen in dental pain. It is safe when used as directed,⁸ and multiple professional societies recommend NSAIDs to treat minor dental pain. With billions of courses of treatment, Aleve® continues to help patients carry on with their daily activities.⁹

References: **1.** Kiersch TA, Halladay SC, Hormel PC. A single-dose, double-blind comparison of naproxen sodium, acetaminophen, and placebo in postoperative dental pain. *Clin Ther.* 1994;16(3):394-404. **2.** American Dental Association announces new policy to combat opioid epidemic. News release. American Dental Association. March 26, 2018. Accessed April 16, 2020. <https://www.ada.org/en/press-room/news-releases/2018-archives/march/american-dental-association-announces-new-policy-to-combat-opioid-epidemic>. **3.** American Association of Oral and Maxillofacial Surgeons. Opioid prescribing: acute and postoperative pain management. Accessed April 16, 2020. https://www.aaoms.org/docs/govt_affairs/advocacy_white_papers/opioid_prescribing.pdf. **4.** ALEVE Caplets. Drug facts. Bayer HealthCare; April 2018. **5.** Data on file, Bayer Consumer Health. **6.** TYLENOL® with codeine prescribing information. Janssen Pharmaceuticals, Inc.; October 2019. **7.** Cooper SA, Desjardins P, Brain P, et al. Longer analgesic effect with naproxen sodium than ibuprofen in post-surgical dental pain: a randomized, double-blind, placebo-controlled, single-dose trial. *Curr Med Res Opin.* 2019;35(12):2149-2158. **8.** Bansal V, Dex T, Proskin H, Garreffa S. A look at the safety profile of over-the-counter naproxen sodium: a meta-analysis. *J Clin Pharmacol.* 2001;41:127-138. **9.** DeArmond B, Francisco CA, Lin J-S, et al. Safety profile of over-the-counter naproxen sodium. *Clin Ther.* 1995;17(4):587-601.

SEM=Standard Error of the Mean.



Aleve, Bayer and the Bayer Cross are registered trademarks of Bayer. All rights reserved unless otherwise indicated. All trademarks are owned by Bayer and its affiliates or licensed for its use. © 2020 Bayer May 2020 PP-AL-P-US-1123

